Burning mouth syndrome (BMS) is a chronic pain disorder the etiology of which has remained unclear. Symptoms associated with BMS vary and may have a negative impact on oral health-related quality of life in patients with BMS (1). McMillan et al. (2) reported that, so far, no therapy has been proven to be effective or ineffective in patients with BMS. To date, there is no clear evidence that the...

OBJECTIVES We investigated the time course of the stromal cell-derived factor 1α (SDF1α) expression and behavior of intravenously administered bone marrow-derived stromal (BMS) cells in the urinary bladder of partial bladder outlet obstruction (PBOO) rats. METHODS Study 1: Recombinant SDF1α or saline was directly injected into the bladder wall of female rats followed by intravenous administra...

BMS-275291 is an p.o. bioavailable, sulfhydryl-based matrix metalloproteinase (MMP) inhibitor currently in clinical development for the treatment of cancer. This inhibitor was designed to potently inhibit MMP activities while minimally affecting those of other metalloproteases (e.g., sheddases) involved in the release of cell-associated molecules such as tumor necrosis factor-alpha, tumor necro...

The concept of an “intelligent building” received significant attention from academic, industry and standard development organizations when technically termed a building management system (BMS). Wireless sensor networks (WSNs) and their recent development enhanced monitoring and control applications for the building’s areas. This paper surveys and analyzes advantages of the main current and eme...

(3S)-(+)-(5-Chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-(trifluoromethyl)-2H-indole-2-one) (MaxiPost, BMS-204352) is a potent and specific opener for maxi-K channels and has potential to prevent and treat ischemic stroke. Following single intravenous doses of [14C]BMS-204352 to rats, only 10 to 12% of radioactivity was extractable from plasma with organic solvents. The unextractable radioact...

Nab-paclitaxel has recently shown greater efficacy in pancreatic ductal adenocarcinoma (PDAC). Insulin like growth factor (IGF) signaling proteins are frequently overexpressed in PDAC and correlate with aggressive tumor phenotype and poor prognosis. We evaluated the improvement in nab-paclitaxel response by addition of BMS-754807, a small molecule inhibitor of IGF-1R/IR signaling, in preclinica...

Tyrosine kinase inhibitor BMS-777067 is an inhibitor of RON/MET receptor tyrosine kinases currently under clinical trials. Here, we report the synergistic activity of BMS-777607 in combination with mTOR inhibitor AZD8055 in killing chemoresistant pancreatic cancer and cancer stem cells. Treatment of pancreatic cancer L3.6pl cells with BMS-777607 alone inhibited clonogenic growth and moderately ...

Activation of mitochondrial ATP-sensitive potassium (mitoK(ATP)) channels protects the brain against ischemic or chemical challenge. Unfortunately, the prototype mitoK(ATP) channel opener, diazoxide, has mitoK(ATP) channel-independent actions. We examined the effects of BMS-191095, a novel selective mitoK(ATP) channel opener, on transient ischemia induced by middle cerebral artery occlusion (MC...

Inhibition of insulin-like growth factor-1 receptor (IGF-1R) signaling represents an attractive therapeutic strategy for cancer treatment. A first-generation IGF-1R inhibitor (R)-4-(3-(3-chlorophenyl)-3-hydroxypropyl)-3-(4-methyl-6-morpholino-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-536924), however, was associated with potent CYP3A4 induction mediated by pregnane X receptor (PXR; NR1I2)...

The cyclic voltammetry of both bulk manganese sulfate (BMS) and nano manganese sulfate (NMS) were studied using 0.1M KCl supporting electrolyte and glassy carbon working electrode. The redox behavior for both bulk (BMS) and MnSO4 (NMS) sulfate was studied voltammetrically in presence and absence of Doxorubicin (DR) using three electrodes system, silver- silver chloride (Ag/AgCl), pla...